Egyptian International Pharmaceutical Industries Co.

As of June 30, 2026, Egyptian International Pharmaceutical Industries Co. carries a market capitalization of 14.75B, placing it among publicly traded companies globally. Its enterprise value stands at 24.56B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Egyptian International Pharmaceutical Industries Co.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, Egyptian International Pharmaceutical Industries Co. has 168.76M shares outstanding.

As of June 30, 2026, Egyptian International Pharmaceutical Industries Co. trades at a trailing price-to-earnings ratio of 10.11. The price-to-sales ratio is 1.49, and the price-to-book ratio stands at 2.42.

As of June 30, 2026, Egyptian International Pharmaceutical Industries Co. trades at an EV/EBITDA multiple of 9.00 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 9.70 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 24.56B versus a market cap of 14.75B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Egyptian International Pharmaceutical Industries Co. maintains a current ratio of 0.97, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 164.53, indicating elevated leverage, while an interest coverage ratio of 2.04 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Egyptian International Pharmaceutical Industries Co. posted a return on equity (ROE) of 27.86, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 13.25 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.27, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.28, useful for judging operating efficiency across full business cycles. Inventory turnover of 1.34 indicates how many times Egyptian International Pharmaceutical Industries Co. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Egyptian International Pharmaceutical Industries Co. recorded 487.08M in income tax expense. That works out to an effective tax rate of 24.96, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.95B, leaving 1.46B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Egyptian International Pharmaceutical Industries Co.'s stock has gained approximately 23.16% over the past 52 weeks. The 50-day moving average sits at 120.16, while the 200-day moving average is 95.00.

Over the twelve months ended June 30, 2026, Egyptian International Pharmaceutical Industries Co. generated 9.91B in revenue and converted that into 1.46B in net income, yielding earnings per share of 8.66. EBITDA reached 2.73B, while operating income came in at 2.61B.

As of June 30, 2026, Egyptian International Pharmaceutical Industries Co. holds 217.97M in cash and equivalents against 10.03B in total debt, resulting in a net debt position of 9.80B. Total book value stands at 6.09B, with working capital of -284.10M providing operational flexibility.

Egyptian International Pharmaceutical Industries Co. produced -1.20B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.67B in capital expenditures, free cash flow totaled -2.88B - equivalent to -17.05 per share.

Over the twelve months ended June 30, 2026, Egyptian International Pharmaceutical Industries Co. posted a gross margin of 42.89, reflecting its pricing power and cost economics. The operating margin of 26.35 and net profit margin of 14.71 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Egyptian International Pharmaceutical Industries Co. paid dividends of 3.24 per share. The dividend payout ratio of 37.13 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -19.51: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -11.54, meaning Egyptian International Pharmaceutical Industries Co. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Egyptian International Pharmaceutical Industries Co.'s most recent stock split took place on May 11, 2023 with a 943:1226 split ratio.

As of June 30, 2026, Egyptian International Pharmaceutical Industries Co. has an Altman Z-Score of 1.79, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.